The psychopharmacology of hallucinogenic agents.
D000818:Animals; D001203:Ascomycota; D001921:Brain / Q000187:drug effects; D002707:Chlordiazepoxide / Q000627:therapeutic use; D002746:Chlorpromazine / Q000627:therapeutic use; D003071:Cognition / Q000187:drug effects; D004361:Drug Tolerance; D004569:Electroencephalography; D004644:Emotions / Q000187:drug effects; D006213:Hallucinogens / Q000008:administration & dosage / Q000032:analysis / Q000494:pharmacology*; D006801:Humans; D008238:Lysergic Acid Diethylamide / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D008635:Mescaline / Q000494:pharmacology; D010465:Perception / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D011955:Receptors, Drug
D006213:Hallucinogens; D011955:Receptors, Drug; D002707:Chlordiazepoxide; D008238:Lysergic Acid Diethylamide; D008635:Mescaline; D002746:Chlorpromazine